EP2948544A4
(en)
|
2013-01-28 |
2016-08-03 |
St Jude Childrens Res Hospital |
CHIMERIC RECEPTOR WITH NKG2D SPECIFICITY FOR CELL THERAPY AGAINST CANCER AND INFECTION DISEASES
|
HUE050787T2
(hu)
*
|
2013-02-26 |
2021-01-28 |
Memorial Sloan Kettering Cancer Center |
Immunterápiás készítmények és eljárások
|
CA2904265C
(en)
*
|
2013-03-15 |
2023-08-08 |
Victor D. FEDOROV |
Compositions and methods for immunotherapy
|
RU2668560C2
(ru)
|
2013-03-29 |
2018-10-02 |
Сумитомо Дайниппон Фарма Ко., Лтд. |
Конъюгированная вакцина на основе пептида антигена wt1
|
US10801070B2
(en)
|
2013-11-25 |
2020-10-13 |
The Broad Institute, Inc. |
Compositions and methods for diagnosing, evaluating and treating cancer
|
WO2015085147A1
(en)
|
2013-12-05 |
2015-06-11 |
The Broad Institute Inc. |
Polymorphic gene typing and somatic change detection using sequencing data
|
KR20230076867A
(ko)
|
2013-12-20 |
2023-05-31 |
더 브로드 인스티튜트, 인코퍼레이티드 |
신생항원 백신과의 병용 요법
|
US11390921B2
(en)
|
2014-04-01 |
2022-07-19 |
Adaptive Biotechnologies Corporation |
Determining WT-1 specific T cells and WT-1 specific T cell receptors (TCRs)
|
US11400115B2
(en)
|
2014-04-23 |
2022-08-02 |
Juno Therapeutics, Inc. |
Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy
|
CA2948462A1
(en)
|
2014-05-15 |
2015-11-19 |
National University Of Singapore |
Modified natural killer cells and uses thereof
|
CN107109419B
(zh)
|
2014-07-21 |
2020-12-22 |
诺华股份有限公司 |
使用cd33嵌合抗原受体治疗癌症
|
EP3177640B1
(en)
|
2014-08-08 |
2020-05-06 |
The Board of Trustees of the Leland Stanford Junior University |
High affinity pd-1 agents and methods of use
|
TWI751102B
(zh)
|
2014-08-28 |
2022-01-01 |
美商奇諾治療有限公司 |
對cd19具專一性之抗體及嵌合抗原受體
|
SG11201703203RA
(en)
|
2014-10-20 |
2017-05-30 |
Juno Therapeutics Inc |
Methods and compositions for dosing in adoptive cell therapy
|
BR112017008710A8
(pt)
*
|
2014-10-27 |
2023-04-25 |
Hutchinson Fred Cancer Res |
Composições e métodos para estimular a eficácia de imunoterapia celular adotiva
|
CN107106670A
(zh)
*
|
2014-10-31 |
2017-08-29 |
宾夕法尼亚大学董事会 |
用于修饰的t细胞的方法和组合物
|
BR112017011909A2
(pt)
|
2014-12-05 |
2018-02-27 |
Eureka Therapeutics Inc |
?antígeno de maturação de célula b alvo de receptores de antígeno quimérico e usos do mesmo?
|
JP7174522B2
(ja)
|
2014-12-05 |
2022-11-17 |
メモリアル スローン ケタリング キャンサー センター |
Fc受容体様5を標的とするキメラ抗原受容体およびその使用
|
NZ732568A
(en)
|
2014-12-05 |
2023-03-31 |
Memorial Sloan Kettering Cancer Center |
Antibodies targeting b-cell maturation antigen and methods of use
|
EP3234193B1
(en)
|
2014-12-19 |
2020-07-15 |
Massachusetts Institute of Technology |
Molecular biomarkers for cancer immunotherapy
|
US20170362297A1
(en)
*
|
2014-12-19 |
2017-12-21 |
Dana-Farber Cancer Institute, Inc. |
Chimeric antigen receptors and methods of use thereof
|
US10993997B2
(en)
|
2014-12-19 |
2021-05-04 |
The Broad Institute, Inc. |
Methods for profiling the t cell repertoire
|
EP3240551A4
(en)
*
|
2014-12-31 |
2018-08-08 |
Anthrogenesis Corporation |
Methods of treating hematological disorders, solid tumors, or infectious diseases using natural killer cells
|
MA41346A
(fr)
|
2015-01-12 |
2017-11-21 |
Juno Therapeutics Inc |
Eléments régulateurs post-transcriptionnels d'hépatite modifiée
|
EP3929296A1
(en)
|
2015-01-30 |
2021-12-29 |
The Regents of The University of California |
Protein delivery in primary hematopoietic cells
|
US20170151281A1
(en)
|
2015-02-19 |
2017-06-01 |
Batu Biologics, Inc. |
Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
|
WO2016138846A1
(en)
|
2015-03-02 |
2016-09-09 |
Shanghai Sidansai Biotechnology Co., Ltd |
Reducing immune tolerance induced by pd‐l1
|
KR20170134525A
(ko)
|
2015-04-02 |
2017-12-06 |
메모리얼 슬로안-케터링 캔서 센터 |
Tnfrsf14 / hvem 단백질 및 이의 이용 방법
|
AU2016248090A1
(en)
|
2015-04-15 |
2017-11-02 |
Prospect CharterCare RWMC, LLC d/b/a Roger Williams Medical Center |
Hepatic arterial infusion of CAR-T cells
|
CA2984180A1
(en)
*
|
2015-04-30 |
2016-11-03 |
University Of Southern California |
Secretory tnt car cell immunotherapy
|
EP3466967A1
(en)
|
2015-05-18 |
2019-04-10 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
JP6515182B2
(ja)
*
|
2015-05-20 |
2019-05-15 |
大日本住友製薬株式会社 |
Wt1抗原ペプチドおよび免疫調節剤の併用
|
IL294183B2
(en)
|
2015-05-20 |
2023-10-01 |
Dana Farber Cancer Inst Inc |
shared neoantigens
|
EP3436575A1
(en)
|
2015-06-18 |
2019-02-06 |
The Broad Institute Inc. |
Novel crispr enzymes and systems
|
WO2016210129A1
(en)
|
2015-06-23 |
2016-12-29 |
Memorial Sloan-Kettering Cancer Center |
Novel pd-1 immune modulating agents
|
WO2016210447A1
(en)
*
|
2015-06-26 |
2016-12-29 |
University Of Southern California |
Masking chimeric antigen receptor t cells for tumor-specific activation
|
WO2017023803A1
(en)
|
2015-07-31 |
2017-02-09 |
Regents Of The University Of Minnesota |
Modified cells and methods of therapy
|
CN105111314B
(zh)
*
|
2015-08-13 |
2019-01-08 |
成都百世博生物技术有限公司 |
一种新型融合蛋白、药物组合物及其制备方法和用途
|
KR20180054824A
(ko)
|
2015-09-29 |
2018-05-24 |
셀진 코포레이션 |
Pd-1 결합 단백질 및 이의 사용 방법
|
BR112018006578A2
(pt)
|
2015-10-01 |
2018-12-26 |
Heat Biologics, Inc. |
composições e métodos para juntar domínios extracelulares tipo i e tipo ii como proteínas quiméricas heterólogas
|
CN106350533B
(zh)
*
|
2015-10-09 |
2020-07-17 |
上海宇研生物技术有限公司 |
Anti-PD-L1-CAR-T及其制备方法和应用
|
WO2017069958A2
(en)
|
2015-10-09 |
2017-04-27 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
WO2017075451A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
|
WO2017075465A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
|
WO2017075478A2
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures
|
CN105331585A
(zh)
*
|
2015-11-13 |
2016-02-17 |
科济生物医药(上海)有限公司 |
携带pd-l1阻断剂的嵌合抗原受体修饰的免疫效应细胞
|
WO2017087708A1
(en)
|
2015-11-19 |
2017-05-26 |
The Brigham And Women's Hospital, Inc. |
Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
|
US10533157B1
(en)
|
2015-12-03 |
2020-01-14 |
Nantbio, Inc. |
Recombinant NK cells expressing co-stimulatory molecules
|
CN116063508A
(zh)
|
2015-12-04 |
2023-05-05 |
纪念斯隆-凯特琳癌症中心 |
靶向Fc受体样5的抗体及使用方法
|
WO2017133175A1
(en)
*
|
2016-02-04 |
2017-08-10 |
Nanjing Legend Biotech Co., Ltd. |
Engineered mammalian cells for cancer therapy
|
CA3014001A1
(en)
*
|
2016-02-25 |
2017-08-31 |
Cell Medica Switzerland Ag |
Binding members to pd-l1
|
EP3443001A4
(en)
|
2016-04-11 |
2020-04-29 |
Obsidian Therapeutics, Inc. |
REGULATED BIOCIRCUIT SYSTEMS
|
WO2017184590A1
(en)
|
2016-04-18 |
2017-10-26 |
The Broad Institute Inc. |
Improved hla epitope prediction
|
EP3452082A1
(en)
|
2016-05-04 |
2019-03-13 |
Fred Hutchinson Cancer Research Center |
Cell-based neoantigen vaccines and uses thereof
|
CN105950561A
(zh)
*
|
2016-05-26 |
2016-09-21 |
江苏杰晟生物科技有限公司 |
一种靶向乳腺癌干细胞的双特异性嵌合抗原受体基因修饰的t淋巴细胞的制备方法及其产品
|
CA3026453A1
(en)
|
2016-06-03 |
2017-12-07 |
Memorial Sloan-Kettering Cancer Center |
Adoptive cell therapies as early treatment options
|
WO2017213979A1
(en)
*
|
2016-06-06 |
2017-12-14 |
St. Jude Children's Research Hospital |
Anti-cd7 chimeric antigen receptor and method of use thereof
|
CN107523547A
(zh)
*
|
2016-06-20 |
2017-12-29 |
上海细胞治疗研究院 |
一种高效稳定表达抑制性抗体的car‑t细胞及其用途
|
CN107523549A
(zh)
*
|
2016-06-20 |
2017-12-29 |
上海细胞治疗研究院 |
一种高效稳定表达激活型抗体的car‑t细胞及其用途
|
CN107523545A
(zh)
*
|
2016-06-20 |
2017-12-29 |
上海细胞治疗研究院 |
一种高效稳定表达抗体的杀伤性细胞及其用途
|
MX2019001185A
(es)
|
2016-07-29 |
2019-10-21 |
Juno Therapeutics Inc |
Polipeptidos inmunomoduladores y composiciones y metodos relacionados.
|
CN117903316A
(zh)
*
|
2016-07-29 |
2024-04-19 |
朱诺治疗学股份有限公司 |
抗独特型抗体及相关方法
|
US11242376B2
(en)
|
2016-08-02 |
2022-02-08 |
TCR2 Therapeutics Inc. |
Compositions and methods for TCR reprogramming using fusion proteins
|
US11630103B2
(en)
|
2016-08-17 |
2023-04-18 |
The Broad Institute, Inc. |
Product and methods useful for modulating and evaluating immune responses
|
WO2018049025A2
(en)
|
2016-09-07 |
2018-03-15 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses
|
US10766958B2
(en)
|
2016-09-19 |
2020-09-08 |
Celgene Corporation |
Methods of treating vitiligo using PD-1 binding antibodies
|
CN109952317A
(zh)
|
2016-09-19 |
2019-06-28 |
细胞基因公司 |
使用pd-1结合蛋白治疗免疫病症的方法
|
EP3518943A4
(en)
*
|
2016-09-28 |
2020-04-22 |
Atossa Therapeutics, Inc. |
METHOD FOR ADAPTIVE CELL THERAPY
|
EP3519433A1
(en)
|
2016-10-03 |
2019-08-07 |
Juno Therapeutics, Inc. |
Hpv-specific binding molecules
|
ES2875959T3
(es)
|
2016-10-07 |
2021-11-11 |
Tcr2 Therapeutics Inc |
Composiciones y métodos para reprogramación de receptores de linfocitos T mediante el uso de proteínas de fusión
|
WO2018067991A1
(en)
|
2016-10-07 |
2018-04-12 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
CN110520530A
(zh)
|
2016-10-18 |
2019-11-29 |
明尼苏达大学董事会 |
肿瘤浸润性淋巴细胞和治疗方法
|
CN107964549B
(zh)
*
|
2016-10-20 |
2020-12-08 |
上海恒润达生生物科技有限公司 |
靶向cd22的嵌合抗原受体及其用途
|
WO2018081784A1
(en)
*
|
2016-10-31 |
2018-05-03 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Artificial antigen presenting cells for expanding immune cells for immunotherapy
|
SG10201912387PA
(en)
|
2016-11-22 |
2020-02-27 |
Nat Univ Singapore |
Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies
|
CA3044593A1
(en)
|
2016-11-22 |
2018-05-31 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
CA3045338A1
(en)
|
2016-12-05 |
2018-06-14 |
Juno Therapeutics, Inc. |
Production of engineered cells for adoptive cell therapy
|
US11242402B2
(en)
|
2016-12-23 |
2022-02-08 |
Macrogenics, Inc. |
ADAM9-binding molecules, and methods of use thereof
|
EP3574116A1
(en)
|
2017-01-24 |
2019-12-04 |
The Broad Institute, Inc. |
Compositions and methods for detecting a mutant variant of a polynucleotide
|
CN108395478A
(zh)
*
|
2017-02-04 |
2018-08-14 |
上海恒润达生生物科技有限公司 |
靶向bcma的嵌合抗原受体并对其双重修饰的方法及其用途
|
US11965892B2
(en)
|
2017-02-12 |
2024-04-23 |
Biontech Us Inc. |
HLA-based methods and compositions and uses thereof
|
CN110300603B
(zh)
|
2017-02-14 |
2023-04-14 |
亘喜生物科技(上海)有限公司 |
Cd47-car-t细胞
|
CN108424461B
(zh)
*
|
2017-02-14 |
2023-03-31 |
亘喜生物科技(上海)有限公司 |
Cd47-car-t细胞
|
CN117357638A
(zh)
|
2017-02-17 |
2024-01-09 |
弗雷德哈钦森癌症中心 |
用于治疗bcma相关癌症和自身免疫性失调的联合疗法
|
BR112019017713A2
(pt)
|
2017-02-27 |
2020-04-07 |
Shattuck Labs Inc |
proteínas quiméricas à base de csf1r
|
WO2018157163A1
(en)
|
2017-02-27 |
2018-08-30 |
Shattuck Labs, Inc. |
Vsig8-based chimeric proteins
|
US11332509B2
(en)
|
2017-02-27 |
2022-05-17 |
Shattuck Labs, Inc. |
Methods of making and using extracellular domain-based chimeric proteins
|
CN117363636A
(zh)
|
2017-03-27 |
2024-01-09 |
新加坡国立大学 |
一种编码嵌合受体的多核苷酸
|
BR112019020001A2
(pt)
|
2017-03-27 |
2020-04-28 |
Nat Univ Singapore |
linhagens celulares estimuladoras para expansão ex vivo e ativação de células exterminadoras naturais
|
CN107082812B
(zh)
*
|
2017-03-29 |
2018-11-13 |
上海科医联创生物科技有限公司 |
一种恢复衰竭性免疫细胞功能的融合蛋白及其应用
|
WO2018183908A1
(en)
|
2017-03-31 |
2018-10-04 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating ovarian tumors
|
WO2018183921A1
(en)
|
2017-04-01 |
2018-10-04 |
The Broad Institute, Inc. |
Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
|
WO2018191553A1
(en)
|
2017-04-12 |
2018-10-18 |
Massachusetts Eye And Ear Infirmary |
Tumor signature for metastasis, compositions of matter methods of use thereof
|
EP3612629A1
(en)
|
2017-04-18 |
2020-02-26 |
The Broad Institute, Inc. |
Compositions for detecting secretion and methods of use
|
JP2020517263A
(ja)
*
|
2017-04-19 |
2020-06-18 |
ユニバーシティ オブ サザン カリフォルニア |
がんを治療するための組成物及び方法
|
KR20200012859A
(ko)
|
2017-04-26 |
2020-02-05 |
유레카 쎄라퓨틱스, 인코포레이티드 |
키메라 활성화 수용체 및 키메라 자극 수용체를 발현하는 세포 및 그의 용도
|
CA3063905A1
(en)
|
2017-05-16 |
2018-11-22 |
The Johns Hopkins University |
Manabodies and methods of using
|
CN108864286B
(zh)
*
|
2017-05-16 |
2023-08-29 |
上海恒润达生生物科技股份有限公司 |
靶向cd19的嵌合抗原受体及联合表达抗pd1抗体可变区的方法和及其用途
|
CA3064000A1
(en)
|
2017-05-24 |
2018-11-29 |
Effector Therapeutics, Inc. |
Methods and compositions for cellular immunotherapy
|
CN107164410B
(zh)
*
|
2017-05-27 |
2019-09-03 |
上海优卡迪生物医药科技有限公司 |
一种基于octs技术的前列腺癌car-t治疗载体及其构建方法和应用
|
CN107245500B
(zh)
*
|
2017-05-27 |
2019-05-17 |
上海优卡迪生物医药科技有限公司 |
一种基于octs技术的淋系白血病car-t治疗载体及其构建方法和应用
|
CN107337736B
(zh)
*
|
2017-06-06 |
2019-07-26 |
上海优卡迪生物医药科技有限公司 |
Octs-car双靶向嵌合抗原受体、编码基因、重组表达载体及其构建和应用
|
CN107325185B
(zh)
*
|
2017-06-06 |
2019-09-20 |
上海优卡迪生物医药科技有限公司 |
基于octs-car的抗psca及pdl1双靶向嵌合抗原受体、编码基因及表达载体
|
WO2018232195A1
(en)
|
2017-06-14 |
2018-12-20 |
The Broad Institute, Inc. |
Compositions and methods targeting complement component 3 for inhibiting tumor growth
|
WO2019006418A2
(en)
|
2017-06-30 |
2019-01-03 |
Intima Bioscience, Inc. |
ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
|
JP7402521B2
(ja)
|
2017-07-11 |
2023-12-21 |
コンパス セラピューティクス リミテッド ライアビリティ カンパニー |
ヒトcd137に結合するアゴニスト性抗体およびその使用
|
CN107337737B
(zh)
*
|
2017-07-18 |
2020-02-07 |
深圳市免疫基因治疗研究院 |
一种嵌合抗原受体及其应用
|
CN107245107B
(zh)
*
|
2017-07-18 |
2020-02-07 |
深圳市免疫基因治疗研究院 |
一种基于cd20的嵌合抗原受体及其应用
|
CN107245106B
(zh)
*
|
2017-07-18 |
2020-06-12 |
深圳市免疫基因治疗研究院 |
一种基于cd10的嵌合抗原受体及其应用
|
CN107312098B
(zh)
*
|
2017-07-18 |
2020-06-12 |
深圳市免疫基因治疗研究院 |
一种基于cd22的嵌合抗原受体及其应用
|
KR20200052349A
(ko)
|
2017-09-11 |
2020-05-14 |
아토사 테라퓨틱스, 인크. |
엔독시펜을 제조 및 사용하는 방법
|
CN107557336B
(zh)
*
|
2017-09-15 |
2020-02-14 |
山东兴瑞生物科技有限公司 |
一种抗muc16安全型嵌合抗原受体修饰的免疫细胞及其应用
|
CA3073848A1
(en)
|
2017-09-21 |
2019-03-28 |
The Broad Institute, Inc. |
Systems, methods, and compositions for targeted nucleic acid editing
|
CN109554349B
(zh)
*
|
2017-09-27 |
2022-06-24 |
亘喜生物科技(上海)有限公司 |
Pd-1基因表达沉默的工程化免疫细胞
|
CN109554348A
(zh)
*
|
2017-09-27 |
2019-04-02 |
亘喜生物科技(上海)有限公司 |
可诱导分泌抗cd47抗体的工程化免疫细胞
|
EP3687569A1
(en)
|
2017-09-29 |
2020-08-05 |
Cell Design Labs, Inc. |
Methods of making bispecific anti-cd307e and anti-bcma chimeric antigen receptors and uses of the same
|
CN109593721B
(zh)
*
|
2017-09-30 |
2022-11-01 |
亘喜生物科技(上海)有限公司 |
具有自杀基因开关的靶向人间皮素的工程化免疫细胞
|
SG11202002728VA
(en)
|
2017-10-03 |
2020-04-29 |
Juno Therapeutics Inc |
Hpv-specific binding molecules
|
US20210069241A1
(en)
|
2017-10-20 |
2021-03-11 |
Fred Hutchinson Cancer Research Center |
Compositions and methods of immunotherapy targeting tigit and/or cd112r or comprising cd226 overexpression
|
WO2019084055A1
(en)
|
2017-10-23 |
2019-05-02 |
Massachusetts Institute Of Technology |
CLASSIFICATION OF GENETIC VARIATION FROM UNICELLULAR TRANSCRIPTOMS
|
WO2019089753A2
(en)
|
2017-10-31 |
2019-05-09 |
Compass Therapeutics Llc |
Cd137 antibodies and pd-1 antagonists and uses thereof
|
SG11202003866QA
(en)
|
2017-11-01 |
2020-05-28 |
Juno Therapeutics Inc |
Chimeric antigen receptors specific for b-cell maturation antigen (bcma)
|
MA49911A
(fr)
|
2017-11-01 |
2020-06-24 |
Juno Therapeutics Inc |
Anticorps et récepteurs antigéniques chimériques spécifiques de l'antigene de maturation des lymphocytes b
|
EP3710039A4
(en)
|
2017-11-13 |
2021-08-04 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS FOR CANCER TREATMENT BY TARGETING THE CLEC2D-KLRB1 PATH
|
CN111655270A
(zh)
*
|
2017-11-14 |
2020-09-11 |
纪念斯隆-凯特琳癌症中心 |
分泌il-36的免疫应答细胞及其用途
|
WO2019096136A1
(zh)
*
|
2017-11-14 |
2019-05-23 |
拜西欧斯(北京)生物技术有限公司 |
抗pd-1抗体及其制备方法和应用
|
US11649294B2
(en)
|
2017-11-14 |
2023-05-16 |
GC Cell Corporation |
Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
|
EP3713961A2
(en)
|
2017-11-20 |
2020-09-30 |
Compass Therapeutics LLC |
Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
|
US11793867B2
(en)
|
2017-12-18 |
2023-10-24 |
Biontech Us Inc. |
Neoantigens and uses thereof
|
CN109971721B
(zh)
*
|
2017-12-28 |
2023-10-31 |
上海细胞治疗研究院 |
自表达cd47抗体的间皮素特异性car-t细胞及其用途
|
CN109971716B
(zh)
*
|
2017-12-28 |
2023-08-01 |
上海细胞治疗研究院 |
自分泌cd47抗体的egfr特异性car-t细胞及其用途
|
CN109971725B
(zh)
*
|
2017-12-28 |
2024-02-02 |
上海细胞治疗研究院 |
抗体修饰的嵌合抗原受体修饰t细胞及其用途
|
CN109971722B
(zh)
*
|
2017-12-28 |
2023-09-01 |
上海细胞治疗研究院 |
靶向cd19且高水平稳定表达cd40抗体的car-t细胞及其用途
|
KR20200106051A
(ko)
*
|
2017-12-29 |
2020-09-10 |
메모리얼 슬로안 케터링 캔서 센터 |
향상된 키메라 항원 수용체 및 그의 용도
|
WO2019136305A1
(en)
*
|
2018-01-04 |
2019-07-11 |
Neumedicines Inc. |
Cell-based and immune checkpoint inhibitor therapies combined with il-12 for treating cancer
|
TW201932593A
(zh)
*
|
2018-01-15 |
2019-08-16 |
美商輝瑞大藥廠 |
合併投與嵌合抗原受體之免疫療法與4-1bb促效劑的方法
|
EP3768700A1
(en)
|
2018-03-23 |
2021-01-27 |
Kite Pharma, Inc. |
Chimeric transmembrane proteins and uses thereof
|
CA3133899A1
(en)
|
2018-03-30 |
2019-10-03 |
University Of Geneva |
Micro rna expression constructs and uses thereof
|
CN112585276A
(zh)
|
2018-04-05 |
2021-03-30 |
朱诺治疗学股份有限公司 |
产生表达重组受体的细胞的方法和相关组合物
|
MA52193A
(fr)
|
2018-04-05 |
2021-02-17 |
Juno Therapeutics Inc |
Récepteurs de lymphocytes t et cellules modifiées les exprimant
|
US11957695B2
(en)
|
2018-04-26 |
2024-04-16 |
The Broad Institute, Inc. |
Methods and compositions targeting glucocorticoid signaling for modulating immune responses
|
EP3784266A4
(en)
*
|
2018-04-26 |
2022-03-16 |
Baylor College of Medicine |
AUTO/ALLO-IMMUN DEFENSE RECEPTORS FOR THE SELECTIVE TARGETING OF PATHOGENIC T LYMPHOCYTES AND ACTIVATED NK CELLS
|
US20210371932A1
(en)
|
2018-06-01 |
2021-12-02 |
Massachusetts Institute Of Technology |
Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
|
BR112020025048A2
(pt)
|
2018-06-13 |
2021-04-06 |
Novartis Ag |
Receptores de antígeno quimérico de bcma e usos dos mesmos
|
SG11202011751WA
(en)
|
2018-06-22 |
2021-01-28 |
Kite Pharma Inc |
Chimeric transmembrane proteins and uses thereof
|
EP3836944A4
(en)
*
|
2018-08-16 |
2022-05-11 |
Memorial Sloan Kettering Cancer Center |
LEUCINE ZIPPER COMPOSITIONS AND METHODS OF USE
|
WO2020068304A2
(en)
|
2018-08-20 |
2020-04-02 |
The Broad Institute, Inc. |
Inhibitors of rna-guided nuclease target binding and uses thereof
|
US20210355522A1
(en)
|
2018-08-20 |
2021-11-18 |
The Broad Institute, Inc. |
Inhibitors of rna-guided nuclease activity and uses thereof
|
WO2020041387A1
(en)
|
2018-08-20 |
2020-02-27 |
The Brigham And Women's Hospital, Inc. |
Degradation domain modifications for spatio-temporal control of rna-guided nucleases
|
US10780121B2
(en)
|
2018-08-29 |
2020-09-22 |
Shattuck Labs, Inc. |
FLT3L-based chimeric proteins
|
EP3856769A4
(en)
*
|
2018-09-28 |
2022-08-17 |
Memorial Sloan Kettering Cancer Center |
IMMUNOREACTIVE CELLS EXPRESSING DOMINANT NEGATIVE FAS AND USES THEREOF
|
US20210382068A1
(en)
|
2018-10-02 |
2021-12-09 |
Dana-Farber Cancer Institute, Inc. |
Hla single allele lines
|
WO2020081730A2
(en)
|
2018-10-16 |
2020-04-23 |
Massachusetts Institute Of Technology |
Methods and compositions for modulating microenvironment
|
US20220170097A1
(en)
|
2018-10-29 |
2022-06-02 |
The Broad Institute, Inc. |
Car t cell transcriptional atlas
|
WO2020092057A1
(en)
|
2018-10-30 |
2020-05-07 |
Yale University |
Compositions and methods for rapid and modular generation of chimeric antigen receptor t cells
|
JP2022513412A
(ja)
*
|
2018-10-31 |
2022-02-07 |
ヒューマニゲン インコーポレイティッド |
癌を治療するための物質及び方法
|
CN113613725A
(zh)
|
2018-11-05 |
2021-11-05 |
路德维格癌症研究所有限公司 |
人源化和变体TGF-β1特异性抗体及其方法和用途
|
CN113613726A
(zh)
|
2018-11-05 |
2021-11-05 |
路德维格癌症研究所有限公司 |
人源化和变体TGF-β3特异性抗体及其方法和用途
|
EP3880215A4
(en)
*
|
2018-11-13 |
2023-02-15 |
Memorial Sloan Kettering Cancer Center |
COMPOSITIONS AND METHODS FOR ADOPTIVE CELL THERAPY FOR CANCER
|
US11046769B2
(en)
|
2018-11-13 |
2021-06-29 |
Compass Therapeutics Llc |
Multispecific binding constructs against checkpoint molecules and uses thereof
|
US20220062394A1
(en)
|
2018-12-17 |
2022-03-03 |
The Broad Institute, Inc. |
Methods for identifying neoantigens
|
JP7236543B2
(ja)
|
2018-12-21 |
2023-03-09 |
ビオンテック ユーエス インコーポレイテッド |
Hlaクラスii特異的エピトープの予測およびcd4+ t細胞の特徴付けのための方法およびシステム
|
US11739156B2
(en)
|
2019-01-06 |
2023-08-29 |
The Broad Institute, Inc. Massachusetts Institute of Technology |
Methods and compositions for overcoming immunosuppression
|
CN113766956B
(zh)
|
2019-03-05 |
2024-05-07 |
恩卡尔塔公司 |
Cd19定向性嵌合抗原受体及其在免疫疗法中的用途
|
US20220154282A1
(en)
|
2019-03-12 |
2022-05-19 |
The Broad Institute, Inc. |
Detection means, compositions and methods for modulating synovial sarcoma cells
|
US20220142948A1
(en)
|
2019-03-18 |
2022-05-12 |
The Broad Institute, Inc. |
Compositions and methods for modulating metabolic regulators of t cell pathogenicity
|
WO2020226854A2
(en)
*
|
2019-04-12 |
2020-11-12 |
The Johns Hopkins University |
Tolerogenic artificial antigen-presenting cells
|
US20220235340A1
(en)
|
2019-05-20 |
2022-07-28 |
The Broad Institute, Inc. |
Novel crispr-cas systems and uses thereof
|
WO2020243371A1
(en)
|
2019-05-28 |
2020-12-03 |
Massachusetts Institute Of Technology |
Methods and compositions for modulating immune responses
|
CN110343667A
(zh)
*
|
2019-07-17 |
2019-10-18 |
贝赛尔特(北京)生物技术有限公司 |
工程化的免疫细胞及其制备方法和应用
|
US20210040175A1
(en)
*
|
2019-08-05 |
2021-02-11 |
Nantkwest, Inc. |
Artificial Target Cells for in-vitro CAR Cytotoxicity and ADCC validation
|
US20220282333A1
(en)
|
2019-08-13 |
2022-09-08 |
The General Hospital Corporation |
Methods for predicting outcomes of checkpoint inhibition and treatment thereof
|
WO2021041922A1
(en)
|
2019-08-30 |
2021-03-04 |
The Broad Institute, Inc. |
Crispr-associated mu transposase systems
|
EP4028413A1
(en)
|
2019-09-10 |
2022-07-20 |
Obsidian Therapeutics, Inc. |
Ca2-il15 fusion proteins for tunable regulation
|
US11793787B2
(en)
|
2019-10-07 |
2023-10-24 |
The Broad Institute, Inc. |
Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
|
US11844800B2
(en)
|
2019-10-30 |
2023-12-19 |
Massachusetts Institute Of Technology |
Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia
|
MX2022005345A
(es)
*
|
2019-11-04 |
2022-08-11 |
Inovio Pharmaceuticals Inc |
Terapia de combinación para el tratamiento de cáncer cerebral.
|
CN112079934B
(zh)
*
|
2019-12-17 |
2021-01-29 |
合源生物科技(天津)有限公司 |
一种靶向cd19的嵌合抗原受体及其用途
|
JP2023538303A
(ja)
|
2020-08-13 |
2023-09-07 |
イェール ユニバーシティー |
所望の表現型を有するcar t細胞の操作および選択のための組成物および方法
|
WO2022036495A1
(en)
|
2020-08-17 |
2022-02-24 |
Utc Therapeutics Inc. |
Lymphocytes-antigen presenting cells co-stimulators and uses thereof
|
EP4203980A1
(en)
*
|
2020-08-28 |
2023-07-05 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Fusion protein enhancing cell therapy
|
CN111925990B
(zh)
*
|
2020-09-02 |
2022-08-26 |
北京立康生命科技有限公司 |
一种针对卵巢癌的Anti-MUC16 CAR-T细胞及其制备方法
|
MX2023005234A
(es)
|
2020-11-06 |
2023-05-18 |
Novartis Ag |
Terapia de combinacion de agente anti-cd19 y agente de direccionamiento a celulas b para el tratamiento de neoplasias malignas de celulas b.
|
JP2023550148A
(ja)
|
2020-11-20 |
2023-11-30 |
シンシア・イノベーション・インコーポレイテッド |
がん免疫治療に用いられる武装二重car-t組成物及び方法
|
WO2022220412A1
(ko)
*
|
2021-04-12 |
2022-10-20 |
메디젠 테라퓨틱스, 인코포레이티드 |
항원에 노출된 cd8 t 세포의 활성화 및 증식 방법 그리고 그에 의해 제조된 항암 활성이 강화된 cd8 t 세포 및 그의 용도
|
WO2022235832A1
(en)
|
2021-05-06 |
2022-11-10 |
Ludwig Institute For Cancer Research Ltd |
Compositions and methods for immunotherapy
|
CA3216709A1
(en)
*
|
2021-05-13 |
2022-11-17 |
Katharine C. Hsu |
Nkg2c+ t cells and methods of use thereof
|
WO2023173137A1
(en)
|
2022-03-11 |
2023-09-14 |
Yale University |
Compositions and methods for efficient and stable genetic modification of eukaryotic cells
|
WO2023220644A1
(en)
|
2022-05-10 |
2023-11-16 |
Yale University |
Compositions and methods of synthetic ctla-4 tails for reprogramming of car-t cells and enhancement of anti-tumor efficacy
|
WO2023243890A1
(ko)
*
|
2022-06-15 |
2023-12-21 |
주식회사 셀리드 |
자연 살해 t 세포의 리간드와 암 항원을 적재한 자연 살해 세포를 포함하는 백신
|
WO2023246840A1
(en)
*
|
2022-06-22 |
2023-12-28 |
Wuhan Houxian Biopharmaceutical Co. Ltd. |
Combination of il-12 and ox40l for cancer immunotherapy
|
WO2024064824A2
(en)
|
2022-09-21 |
2024-03-28 |
Yale University |
Compositions and methods for identification of membrane targets for enhancement of nk cell therapy
|
WO2024077256A1
(en)
|
2022-10-07 |
2024-04-11 |
The General Hospital Corporation |
Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins
|
CN115850519B
(zh)
*
|
2022-12-12 |
2023-06-23 |
南京市浦口医院 |
一种靶向MAGE-A1且自分泌CD47 scFv的嵌合抗原受体及其应用
|